Dr. Gary Novack was quoted in an article on ophthalmic drug delivery in the May 2018 issue of ASCRS‘s EyeWorld. Dr. Novack pointed out “…In considering what molecules might be most likely to succeed in a sustained delivery approach…this depends on the type of delivery system. If it’s a zero order, i.e., constant delivery with respect to time system, a molecule like brimonidine or timolol is most appropriate,” … “If it’s a pulsatile, i.e., peaks and troughs system, a molecule like the prostaglandins is the better choice.” Dr. Novack has published several articles on issues in ophthalmic drug delivery, and worked on a number of successful products in this area.
There’s a lot of talk and confusion of the issues involved in the role of compounding pharmacies for topical ocular medications (eyedrops). Please see this interview in EyeWorld in which I am interviewed about regulatory issues. I address the special role which compounding pharmacies have played in the therapeutic process as physicians tailor therapies to individual patients. At the same time, I discuss the issues in the use of compounding pharmacies for larger populations crossing state lines.
One of Dr. Novack’s articles was the most popular Ophthalmology article on Medscape (Novack GD, Cannabinoids for treatment of glaucoma, Curr Opin Ophthalmol. 2016 Mar;27(2):146-50).
Dr. Novack published three recent key articles in leading ophthalmology journals. These are:
-How FDA views post-hoc analyses (moving the target after the arrow has been shot): Novack GD. The importance of a priori statistical planning in controlled clinical trials. Am J Ophthalmology 2015;160(1):4-5.
-Patient payments for prescription medications (Novack GD. What determines how much your patient pays for their medication in the United States? Am J Ophthalmol 2016;167(48-51).
View all articles by Gary D. Novack on the American Journal of Opthamology website.
-A “unified field theory” of treatment adherence and performance (Novack GD. Time to take your medicines, seriously. Ocul Surf 2016;14(3):410-415.)
View all articles by Gary D. Novack on the Ocular Surface Journal website.
Together, these articles provide insight on the unique perspective of Dr. Novack on drug development.
Also recently published was an overall review of ocular pharmacology (Novack GD, Robin AL. Ocular Pharmacology. J Clin Pharmacol 206: 56(5): 517-527. (ISSN)1552-4604, and an updated review of the utility of cannabinoids in the treatment of glaucoma (Novack GD. Cannabinoids for treatment of glaucoma. Curr Opin Ophthalmology 27(2): 146-150).
A complete list of Dr. Novack’s over 240 publications may be found at https://www.pharmalogic.com/publications/
Dr. Novack’s 200th paper was published (Eyes on new product development: trabecular meshwork. J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):83-4). This was a special article of his regular column in this journal, in which he noted the late Dr. David Epstein’s challenge to treat damaged trabecular outflow in glaucoma. www.ncbi.nlm.nih.gov
Among the many papers and abstracts published in 2011, Dr. Novack was an author on a Phase 2a study of a novel rho kinase inhibitor for the treatment of glaucoma:
Williams RD, Novack GD, van Haarlem T, Kopczynski C for the AR-12286 Phase 2a Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 2011:152: 834-841.